RRRodrigo Cesar de Lima Resende

Rodrigo Cesar de Lima Resende

*This is an algorithmically generated author record based on publicly available information.

Rodrigo Cesar de Lima Resende has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hereditary multiple exostosis: a case report and brief review regarding the risk of malignancy

    by Joelma Pereira Costa, Renan da Silva Bentes, Matheus Mychael Mazzaro Conchy, Lorena Pacheco de Carvalho, Rodrigo Cesar de Lima Resende, Edson Antonacci Júnior

    Osteocartilaginous exostoses is the most common benign bone tumor of childhood whose predominant growth on cartilage with potential impact on bone development and architecture, with potential risk of fractures and installation of malignant neoplasms. We present a case of an 11 -year -old female child, admitted to the unit complained of pain in the proximal region of the left ulna and distal third of the ipsilateral tibia with evolution of one year and suspected hereditary multiple exostosis whose histopathological result was positive for osteochondroma. The conduct for this case consisted of surgical extraction of the bone mass and outpatient follow -up for the case of relevant angular deviation of limbs, fractures or emergence of neoplasia suspected of malignancy.


  • Open Access

    Auricular vagus nerve stimulation: a new option to treat inflammation in COVID-19?

    by Fernando Mendes Sant’aNna, Rodrigo César Lima Resende, Lucas Bonacossa Sant’aNna, Sérgio Lívio Menezes Couceiro, Romero Bonacossa Soares Pinto, Mariana Bonacossa Sant’aNna, Liaw Wen Chao, Jozsef Constantin Szeles, Eugenijus Kaniusas

    COVID-19 is an infectious disease caused by the new coronavirus (SARS-CoV-2), which invades alveolar epithelial cells through angiotensin-2 converting enzyme (ACE2) receptors1 1 Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-80.e8. https://doi.org/10.1016/j.cell.2020.02.052 https://doi.org/10.1016/j.cell.2020.02.0... ,2 2 Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-60. https://doi.org/10.1038/s41569-020-0360-5 https://doi.org/10.1038/s41569-020-0360-... . Infection is triggered by the binding of the spike protein (S) of SARS-CoV-1 or SARS-CoV-2 to ACE23 3 Costa IBSDS, Bittar CS, Rizk SI, Araújo Filho AE, Santos KAQ, Machado TIV, et al. The heart and COVID-19: what cardiologists need to know. Arq Bras Cardiol. 2020;114(5):805-16. https://doi.org/10.36660/abc.20200279 https://doi.org/10.36660/abc.20200279... and, through this binding, the virus enters the host cell, where ACE2 is later inactivated. As this enzyme is abundantly found in alveolar epithelial cells and in the myocardium, potentially serious damage can occur in the lungs and heart2 2 Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-60. https://doi.org/10.1038/s41569-020-0360-5 https://doi.org/10.1038/s41569-020-0360-... ,4 4 Vellingiri B, Jayaramayya K, Iyer M, Narayanasamy A, Govindasamy V, Giridharan B, et al. COVID-19: a promising cure for the global panic. Sci Total Environ. 2020;725:138277. https://doi.org/10.1016/j.scitotenv.2020.138277 https://doi.org/10.1016/j.scitotenv.2020... .